TOKENPOST
1 min read
Add as a preferred source on Google

China Approves Eli Lilly’s Orforglipron Weight-Loss Pill

Lilly is the first drugmaker to receive Chinese clearance for a GLP-1 weight-loss pill, giving it an early lead over Novo Nordisk.

By Riza Dagoc
Published
An unmarked tablet rests in an open hand outside a government building / TokenPost.ai
An unmarked tablet rests in an open hand outside a government building / TokenPost.ai

China’s medicine regulator approved Eli Lilly’s oral GLP-1 weight-loss drug orforglipron, making Lilly the first drugmaker cleared for a GLP-1 weight-loss pill in the country and giving it an early lead over Novo Nordisk.

Orforglipron is the active ingredient in Foundayo. An EU expert panel has also recommended marketing authorization for Foundayo, moving the pill closer to possible approval in Europe.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…